Holen Sie sich die Stockscreener-App
41.34
7.15%
2.865
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - marketscreener.com
Veracyte stock (US92347M1009): earnings momentum and cancer diagnostics focus - AD HOC NEWS
Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test - Moomoo
Veracyte (VCYT) Gains CMS Coverage for TrueMRD Monitoring Test - GuruFocus
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test - Contract Pharma
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TipRanks
Veracyte’s bladder cancer test receives Medicare coverage - Investing.com
Veracyte secures Medicare coverage for Truemrd monitoring test in muscle-invasive bladder cancer - marketscreener.com
Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer - TradingView
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings - simplywall.st
Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are - Yahoo Finance
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors - GuruFocus
Artisan Partners (NYSE: VCYT) reports 5.50M shares, 6.9% stake in Veracyte - Stock Titan
Morgan Stanley Initiates Veracyte(VCYT.US) With Sell Rating, Announces Target Price $39.7 - Moomoo
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte - Stock Titan
State of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Stapley Marc - Moomoo
Why Veracyte Stock Is Skyrocketing Higher This Week - AOL.com
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies - simplywall.st
Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23%News and Statistics - IndexBox
Veracyte, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-05-08 - Seeking Alpha
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte SVP McGuire sells $398,211 in shares By Investing.com - Investing.com South Africa
Veracyte SVP McGuire sells $398,211 in shares - Investing.com India
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan - Stock Titan
Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Number of shareholders of Veracyte, Inc. – MUN:12V - TradingView
Veracyte price target raised to $42 from $40 at Canaccord - TipRanks
Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives - Sahm
VCYT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
The Nasdaq Biotechnology Index closed up more than 2.1%. Among its constituents, Pyxis Oncology rose 25.68%, Veracyte gained 25.08%, MannKind (MNKD) increased 24.83%, Replimune was up 19.16%, and Novavax (NVAX) rose 15.56%. - Bitget
Veracyte (VCYT) Jumps As Strong Q1 Fuels Bullish Guidance - timothysykes.com
Ann McGuire sells 6,658 shares under 10b5-1 plan (VCYT) - Stock Titan
Veracyte Surges 21.1% Amid Sector-Wide Rally - AlphaStreet
UBS Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Veracyte, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Key Risks, and Results Overview - Minichart
VCYT Stock Jumps As Raised Guidance Fuels Bullish Momentum - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
FMR LLC (NASDAQ: VCYT) discloses 9.7% holding — 7.7M shares - Stock Titan
UBS Adjusts Price Target on Veracyte to $52 From $48, Maintains Buy Rating - marketscreener.com
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $42 to $48 - Moomoo
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript - Insider Monkey
Veracyte, Inc. 1Q 2026: Revenue $139.07M, EPS $0.35— 10-Q Summary - TradingView
Veracyte (NASDAQ: VCYT) Q1 profit surges as revenue climbs 21% - Stock Titan
Veracyte Q1 2026 slides: EPS beats by 57%, guidance raised - Investing.com Australia
Veracyte Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Revenue Guidance; Shares Up Pre-Bell - marketscreener.com
Veracyte: Raising FY26 Testing Rev Guidance to $570M to $580M >VCYT - Moomoo
Veracyte Announces First Quarter 2026 Financial Results - BioSpace
Veracyte Q1 Earnings Call Highlights - Yahoo Finance
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Earnings call transcript: Veracyte Q1 2026 beats EPS forecast by 57% - Investing.com UK
Veracyte Inc Earnings Call Signals Profitable Growth - TipRanks
Veracyte, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge - ChartMill
Earnings call transcript: Veracyte Q1 2026 beats EPS forecast by 57% By Investing.com - Investing.com Australia
1.19%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):